Literature DB >> 8730782

NGF as a mediator of inflammatory pain.

S B McMahon1.   

Abstract

The chapter reviews some of recent evidence which suggests that one neurotrophin, nerve growth factor (NGF), is a peripherally produced mediator of some persistent pain states, notably those associated with inflammation. The evidence for this proposal is as follows. 1. The endogenous production of NGF regulates the sensitivity of nociceptive systems. Behavioural and electrophysiological studies have shown that sequestration of constitutively produced NGF leads to decrease nociceptor sensitivity. 2. In a wide variety of experimental inflammatory conditions NGF levels are rapidly increased in the inflamed tissue. 3. The high-affinity NGF receptor, trkA, is selectively expressed by nociceptive sensory neurons particularly those containing sensory neuropeptides such as substance P and CGRP. 4. The systematic or local application of exogenous NGF produces a rapid and prolonged behavioural hyperalgesia in both animals and humans. Exogenous NGF has also been found to activate and sensitize fine calibre sensory neurons. 5. In a number of animal models, much of the hyperalgesia associated with experimental inflammation is blocked by pharmacological "antagonism' of NGF. The mechanisms by which NGF up-regulation in inflamed tissues might lead to sensory abnormalities is also discussed. In particular, evidence is reviewed which suggests that increased NGF levels leads to both peripheral sensitization of nociceptors and central sensitization of dorsal horn neurons responding to noxious stimuli.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8730782     DOI: 10.1098/rstb.1996.0039

Source DB:  PubMed          Journal:  Philos Trans R Soc Lond B Biol Sci        ISSN: 0962-8436            Impact factor:   6.237


  70 in total

Review 1.  Peripheral nerve regeneration and neurotrophic factors.

Authors:  G Terenghi
Journal:  J Anat       Date:  1999-01       Impact factor: 2.610

Review 2.  Mechanism of cancer pain.

Authors:  Brian L Schmidt; Darryl T Hamamoto; Donald A Simone; George L Wilcox
Journal:  Mol Interv       Date:  2010-06

Review 3.  Putative therapeutic targets in the treatment of visceral hyperalgesia.

Authors:  S Collins
Journal:  Gut       Date:  2004-03       Impact factor: 23.059

4.  Effects of terbutaline on NGF formation in allergic inflammation of the rat.

Authors:  R Amann; B A Peskar; R Schuligoi
Journal:  Br J Pharmacol       Date:  2001-05       Impact factor: 8.739

Review 5.  Peripheral mechanisms of pain and analgesia.

Authors:  Christoph Stein; J David Clark; Uhtaek Oh; Michael R Vasko; George L Wilcox; Aaron C Overland; Todd W Vanderah; Robert H Spencer
Journal:  Brain Res Rev       Date:  2008-12-31

6.  Excitability parameters and sensitivity to anemone toxin ATX-II in rat small diameter primary sensory neurones discriminated by Griffonia simplicifolia isolectin IB4.

Authors:  Alistair Snape; James F Pittaway; Mark D Baker
Journal:  J Physiol       Date:  2009-11-09       Impact factor: 5.182

Review 7.  Interstitial cystitis: the painful bladder syndrome.

Authors:  R Doggweiler-Wiygul; J Blankenship; S A MacDiarmid
Journal:  Curr Rev Pain       Date:  2000

8.  In vivo regulation of NGF-mediated functions by Nedd4-2 ubiquitination of TrkA.

Authors:  Tao Yu; Laura Calvo; Begoña Anta; Saray López-Benito; Roger López-Bellido; Cristina Vicente-García; Lino Tessarollo; Raquel E Rodriguez; Juan C Arévalo
Journal:  J Neurosci       Date:  2014-04-23       Impact factor: 6.167

9.  Potential mechanisms for hypoalgesia induced by anti-nerve growth factor immunoglobulin are identified using autoimmune nerve growth factor deprivation.

Authors:  E M Hoffman; Z Zhang; M B Anderson; R Schechter; K E Miller
Journal:  Neuroscience       Date:  2011-07-28       Impact factor: 3.590

10.  Glial cell line-derived neurotrophic factor family ligands enhance capsaicin-stimulated release of calcitonin gene-related peptide from sensory neurons.

Authors:  B S Schmutzler; S Roy; C M Hingtgen
Journal:  Neuroscience       Date:  2009-03-11       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.